UY23665A1 - Procedimiento para la preparacion de compuesto farmaceutico - Google Patents
Procedimiento para la preparacion de compuesto farmaceuticoInfo
- Publication number
- UY23665A1 UY23665A1 UY23665A UY23665A UY23665A1 UY 23665 A1 UY23665 A1 UY 23665A1 UY 23665 A UY23665 A UY 23665A UY 23665 A UY23665 A UY 23665A UY 23665 A1 UY23665 A1 UY 23665A1
- Authority
- UY
- Uruguay
- Prior art keywords
- procedure
- preparation
- pharmaceutical compound
- gel
- active compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
Abstract
Procedimiento para la preparación de composiciones farmacéuticas que forman un gel de lecitina in vivo para la liberación mantenida de un compuesto biológicamente activo que comprende: a- una parte en peso de un disolvente orgánico farmacéuticamente aceptable que no es sustancialmente soluble en agua; b- una cantidad terapéuticamente efectiva de dicho compuesto biológicamente activo que se dispersa en dicho disolvente; y c- un acelerador de 0,1 a alrededor 0,2 partes en peso de una lecitina que se dispersa en un disolvente farmacéuticamente aceptable que no sea sustancialmente soluble en agua, adicionar el ingrediente activo y homogeneizar la mezcla. En una realización particular el biológicamente activo es interferón alfa o es un factor liberador de hormona en desarrollo o un análogo respectivo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96075292A | 1992-10-14 | 1992-10-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY23665A1 true UY23665A1 (es) | 1994-04-06 |
Family
ID=25503572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY23665A UY23665A1 (es) | 1992-10-14 | 1993-10-13 | Procedimiento para la preparacion de compuesto farmaceutico |
Country Status (19)
Country | Link |
---|---|
US (1) | US5863549A (es) |
EP (1) | EP0620740B1 (es) |
JP (1) | JP2613750B2 (es) |
CN (1) | CN1090509A (es) |
AT (1) | ATE180976T1 (es) |
AU (1) | AU672441B2 (es) |
CA (1) | CA2125784A1 (es) |
DE (1) | DE69325256T2 (es) |
ES (1) | ES2133413T3 (es) |
IL (1) | IL107207A0 (es) |
IS (1) | IS4083A (es) |
LV (1) | LV10180A (es) |
MX (1) | MX9306239A (es) |
NZ (1) | NZ256413A (es) |
RU (1) | RU94033520A (es) |
SI (1) | SI9300468A (es) |
UY (1) | UY23665A1 (es) |
WO (1) | WO1994008623A1 (es) |
ZA (1) | ZA937459B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595760A (en) * | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US6379631B1 (en) | 1996-06-28 | 2002-04-30 | Johnson & Johnson Medical, Inc. | Instrument sterilization container formed of a liquid crystal polymer |
US6264902B1 (en) | 1996-06-28 | 2001-07-24 | Johnson & Johnson Medical, Inc. | Instrument sterilization container having an improved latching mechanism |
SK20012000A3 (sk) * | 1998-06-29 | 2001-08-06 | Pharmaceuticals Applications Asociates, Llc | Transdermálny prostriedok na zmiernenie bolesti |
JP2002521331A (ja) * | 1998-07-20 | 2002-07-16 | ペプテック リミテッド | バイオインプラント製剤 |
AU755443C (en) * | 1998-07-20 | 2006-08-17 | Virbac (Australia) Pty Limited | Bioimplant formulation |
US8052982B2 (en) | 1998-07-20 | 2011-11-08 | Peptech Animal Health Pty Limited | Bioimplant formulation comprising lecithin and stearin |
EP1064934A1 (en) * | 1999-06-30 | 2001-01-03 | Applied Research Systems ARS Holding N.V. | GRF-containing lyophilized pharmaceutical composition |
US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
US20020106406A1 (en) * | 2000-12-08 | 2002-08-08 | Mchugh Anthony J. | Crystallizable/non-crystallizable polymer composites |
GB0117057D0 (en) * | 2001-07-12 | 2001-09-05 | Ferring Bv | Pharmaceutical composition |
CA2474613A1 (en) | 2002-03-04 | 2003-09-18 | Jacques-Pierre Moreau | Sustained release drug formulations containing a carrier peptide |
NZ535270A (en) | 2002-03-12 | 2006-11-30 | Univ Montreal | Composition having gelling properties for the sustained delivery of bioactive substances |
KR100906547B1 (ko) | 2002-03-12 | 2009-07-07 | 에띠빠흠 | 생활성 물질의 지속적 전달을 위한 겔화 특성을 갖는 조성물 |
US20040025791A1 (en) * | 2002-08-09 | 2004-02-12 | Applied Materials, Inc. | Etch chamber with dual frequency biasing sources and a single frequency plasma generating source |
FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
JP2008502690A (ja) * | 2004-06-15 | 2008-01-31 | アンドリュー シァン チェン, | リン脂質組成物ならびにその調製方法および使用方法 |
US7858115B2 (en) * | 2004-06-24 | 2010-12-28 | Idexx Laboratories | Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
AU2006241072A1 (en) * | 2005-04-25 | 2006-11-02 | Amgen Inc. | Biodegradable peptide sustained release compositions containing porogens |
US7695633B2 (en) * | 2005-10-18 | 2010-04-13 | Applied Materials, Inc. | Independent control of ion density, ion energy distribution and ion dissociation in a plasma reactor |
CU23432B6 (es) * | 2005-11-02 | 2009-10-16 | Ct Ingenieria Genetica Biotech | Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras |
SI1787658T1 (sl) | 2005-11-10 | 2012-07-31 | Chemi Spa | Formulacije z trajnim sproščanjem somatostatin analognih inhibitorjev rastnega hormona |
US8017159B2 (en) * | 2005-11-16 | 2011-09-13 | Idexx Laboratories, Inc. | Phospholipid gel compositions for delivery of aptamers and methods of treating conditions using same |
US20070245958A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling ion radial distribution |
US7727413B2 (en) * | 2006-04-24 | 2010-06-01 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source to control plasma ion density |
US20070245960A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion density |
US20070245961A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Dual plasma source process using a variable frequency capacitively coupled source for controlling plasma ion dissociation |
US7780864B2 (en) * | 2006-04-24 | 2010-08-24 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma sources for controlling plasma ion radial distribution |
US20070246443A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Process using combined capacitively and inductively coupled plasma process for controlling plasma ion dissociation |
US20070246162A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with an inductive plasma source and a VHF capacitively coupled plasma source with variable frequency |
US20070246163A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with independent capacitive and inductive plasma sources |
US7645357B2 (en) * | 2006-04-24 | 2010-01-12 | Applied Materials, Inc. | Plasma reactor apparatus with a VHF capacitively coupled plasma source of variable frequency |
US20070246161A1 (en) * | 2006-04-24 | 2007-10-25 | Applied Materials, Inc. | Plasma reactor apparatus with a toroidal plasma source and a VHF capacitively coupled plasma source with variable frequency |
US7403325B2 (en) * | 2006-05-19 | 2008-07-22 | Xerox Corporation | Electrophoretic display device |
WO2009039628A1 (en) | 2007-09-27 | 2009-04-02 | Immunovaccine Technologies Inc. | Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo |
US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
TWI442932B (zh) * | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以GnRH拮抗劑治療攝護腺癌的方法 |
WO2009114959A1 (zh) * | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
AU2009253780B2 (en) * | 2008-06-05 | 2014-08-14 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
NZ595767A (en) * | 2009-05-01 | 2012-12-21 | Ferring Bv | Composition for the treatment of prostate cancer |
TW201043221A (en) * | 2009-05-06 | 2010-12-16 | Ferring Int Ct Sa | Kit and method for preparation of a Degarelix solution |
US20110039787A1 (en) * | 2009-07-06 | 2011-02-17 | Ferring International Center S.A. | Compositions, kits and methods for treating benign prostate hyperplasia |
CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
NZ608210A (en) | 2010-08-20 | 2015-02-27 | Reddy’S Lab Ltd Dr | Phospholipid depot |
PT2629779T (pt) | 2010-10-22 | 2017-09-22 | Dr Reddy's Laboratories Sa | Utilização de depósito de fosfolípidos viscosos estáveis em armazenamento para tratar feridas |
EP2447276A1 (en) | 2010-10-27 | 2012-05-02 | Ferring B.V. | Process for the manufacture of Degarelix and its intermediates |
ES2617336T3 (es) | 2010-10-27 | 2017-06-16 | Ferring B.V. | Procedimiento para la fabricación de degarelix y sus productos intermedios |
JO3755B1 (ar) | 2011-01-26 | 2021-01-31 | Ferring Bv | تركيبات تستوستيرون |
CA2838739A1 (en) * | 2011-06-09 | 2012-12-13 | Hailiang Chen | Gel compositions |
IN2014CN02581A (es) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
IN2014MN02213A (es) | 2012-05-10 | 2015-07-10 | Painreform Ltd | |
AR092840A1 (es) | 2012-06-01 | 2015-05-06 | Ferring Bv | Elaboracion de degarelix |
KR102227966B1 (ko) * | 2019-06-26 | 2021-03-16 | 주식회사 엠이티라이프사이언스 | 비활성 폴리펩타이드 trp의 약제학적 제형 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4377567A (en) * | 1978-10-02 | 1983-03-22 | The Procter & Gamble Company | Lipid membrane drug delivery |
US4252793A (en) * | 1979-06-18 | 1981-02-24 | American Lecithin Company | Injectable lecithin preparation |
US4297353A (en) * | 1980-08-04 | 1981-10-27 | Sandoz, Inc. | Non-irritating injectable dosage forms |
US4578391A (en) * | 1982-01-20 | 1986-03-25 | Yamanouchi Pharmaceutical Co., Ltd. | Oily compositions of antitumor drugs |
FR2562421B1 (fr) * | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
US4761288A (en) * | 1984-09-24 | 1988-08-02 | Mezei Associates Limited | Multiphase liposomal drug delivery system |
GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
US5084269A (en) * | 1986-11-06 | 1992-01-28 | Kullenberg Fred W | Adjuvant for dose treatment with antigens |
NZ222907A (en) * | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
CH681427A5 (es) * | 1987-07-01 | 1993-03-31 | Zambon Spa | |
JP2643217B2 (ja) * | 1988-01-22 | 1997-08-20 | エーザイ株式会社 | 脂溶性物質水性液 |
US5124151A (en) * | 1990-08-07 | 1992-06-23 | Mediventures Inc. | Drug delivery by injection with thermo-irreversible gels |
US5143731A (en) * | 1990-08-07 | 1992-09-01 | Mediventures Incorporated | Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels |
US5505877A (en) * | 1991-10-15 | 1996-04-09 | Krivohlavek; Dennis | Making multiple phase emulsion or gel |
DE4201527A1 (de) * | 1992-01-21 | 1993-07-22 | Knoll Ag | Lecithinhaltige loesungen mit levemopamil |
US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
-
1993
- 1993-09-08 SI SI9300468A patent/SI9300468A/sl unknown
- 1993-10-05 AU AU51110/93A patent/AU672441B2/en not_active Ceased
- 1993-10-05 EP EP93921914A patent/EP0620740B1/en not_active Expired - Lifetime
- 1993-10-05 CA CA002125784A patent/CA2125784A1/en not_active Abandoned
- 1993-10-05 DE DE69325256T patent/DE69325256T2/de not_active Expired - Fee Related
- 1993-10-05 JP JP6509578A patent/JP2613750B2/ja not_active Expired - Fee Related
- 1993-10-05 ES ES93921914T patent/ES2133413T3/es not_active Expired - Lifetime
- 1993-10-05 AT AT93921914T patent/ATE180976T1/de not_active IP Right Cessation
- 1993-10-05 NZ NZ256413A patent/NZ256413A/en unknown
- 1993-10-05 RU RU94033520/14A patent/RU94033520A/ru unknown
- 1993-10-05 WO PCT/EP1993/002711 patent/WO1994008623A1/en active IP Right Grant
- 1993-10-06 IL IL107207A patent/IL107207A0/xx unknown
- 1993-10-07 ZA ZA937459A patent/ZA937459B/xx unknown
- 1993-10-07 MX MX9306239A patent/MX9306239A/es unknown
- 1993-10-13 CN CN93119112A patent/CN1090509A/zh active Pending
- 1993-10-13 UY UY23665A patent/UY23665A1/es unknown
- 1993-10-13 IS IS4083A patent/IS4083A/is unknown
- 1993-10-13 LV LV931150A patent/LV10180A/xx unknown
-
1996
- 1996-08-22 US US08/701,274 patent/US5863549A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ATE180976T1 (de) | 1999-06-15 |
JP2613750B2 (ja) | 1997-05-28 |
CA2125784A1 (en) | 1994-04-28 |
CN1090509A (zh) | 1994-08-10 |
AU672441B2 (en) | 1996-10-03 |
JPH06511263A (ja) | 1994-12-15 |
IS4083A (is) | 1994-04-15 |
EP0620740A1 (en) | 1994-10-26 |
NZ256413A (en) | 1996-07-26 |
AU5111093A (en) | 1994-05-09 |
RU94033520A (ru) | 1996-11-10 |
EP0620740B1 (en) | 1999-06-09 |
DE69325256T2 (de) | 1999-12-16 |
LV10180A (lv) | 1994-10-20 |
WO1994008623A1 (en) | 1994-04-28 |
DE69325256D1 (de) | 1999-07-15 |
SI9300468A (en) | 1994-06-30 |
MX9306239A (es) | 1994-06-30 |
US5863549A (en) | 1999-01-26 |
IL107207A0 (en) | 1994-01-25 |
ES2133413T3 (es) | 1999-09-16 |
ZA937459B (en) | 1994-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY23665A1 (es) | Procedimiento para la preparacion de compuesto farmaceutico | |
EP0962225A3 (en) | Use of phentolamine for the manufacture of a medicament for the treatment of erectile dysfunction | |
BRPI0015284B8 (pt) | formulações de hidrocodona de liberação controlada | |
ES2116986T3 (es) | Composiciones de metal-peptidos y metodos cosmeticos para estimular el crecimiento del cabello. | |
ATE237285T1 (de) | Medizinisches implantat | |
HUP0100437A2 (hu) | Szabályzott felszabadulású gyógyszerkészítmény tolterodin adagolására | |
NL300382I1 (nl) | Treatment of pompe's disease | |
HK1029925A1 (en) | Cannabinol-11-oic acid derivatives useful as antiinflammatory agents and analgesics | |
DE69615561T2 (de) | Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe | |
PT668763E (pt) | Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento | |
PT950057E (pt) | Enantiomeros de 3-piridilo e sua utilizacao como analgesicos | |
EP0734723A4 (en) | THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS | |
PT998287E (pt) | Utilizacao de levobupivacaina | |
ES2160643T3 (es) | Composiciones que contienen g-csf y proteina de union al tnf. | |
HUP0003840A2 (hu) | Szabályozott hatóanyagleadású gyógyászati készítmények | |
DK0412554T3 (da) | Sustained-release-præparat til administration i hjernen | |
ATE458471T1 (de) | Formulierungen mit povidon-iod zur behandlung von wunden | |
DE69111974D1 (de) | Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum. | |
MY104521A (en) | Treatment of depression. | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE306278T1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
ATE147978T1 (de) | Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit | |
EP0301449A3 (en) | Enantiomers of propafenone-containing therapeutic agents | |
ATE12649T1 (de) | Optisch aktives dipeptide, seine pharmazeutisch vertraeglichen salze, verfahren zur herstellung und diese enthaltende pharmazeutische praeparate. | |
ITMI910133A0 (it) | Derivati salini del gliceril fosforil mioinositolo ad attivita' terapeutica procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |